Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-22-004669
Filing Date
2022-02-28
Accepted
2022-02-28 17:16:25
Documents
8
Period of Report
2022-04-14

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A dffn20220228_def14a.htm DEF 14A 289486
2 arr.jpg GRAPHIC 2565
3 dffn20220218_pre14aimg001.gif GRAPHIC 6957
4 dffn20220218_pre14aimg002.jpg GRAPHIC 7463
5 dffn20220218_pre14aimg003.jpg GRAPHIC 7463
6 internet.jpg GRAPHIC 7270
7 mail.jpg GRAPHIC 10763
8 phone.jpg GRAPHIC 6272
  Complete submission text file 0001437749-22-004669.txt   358241
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37942 | Film No.: 22691429
SIC: 2834 Pharmaceutical Preparations